山东步长制药股份有限公司关于控股子公司完成工商变更登记的公告

Group 1 - Company held a board meeting on May 26, 2025, to approve the change of legal representative for its subsidiary, Shandong Buchang Zhongxin Kang Pharmaceutical Technology Co., Ltd. [1] - The new legal representative is Chen Xuebo, and the registered capital of the subsidiary is 5 million [1] - The subsidiary's business scope includes technology services, medical device sales, and health food sales among others [1] Group 2 - The controlling shareholder, Buchang (Hong Kong), holds 490,957,202 shares, accounting for 46.56% of the total share capital [2][3] - After the recent release of part of the pledged shares, Buchang (Hong Kong) has a total of 89,930,000 shares pledged [3] - The total shares held by Buchang (Hong Kong) and its concerted parties amount to 598,200,660 shares, representing 56.72% of the total share capital [3]